When TMS Is Denied: How the Appeals Process Works

A denial of TMS prior authorization is not the end of the conversation. Most TMS denials are denials of documentation rather than denials of clinical appropriateness, and a structured appeals path exists precisely for that reason. The three escalation levels — peer-to-peer review, formal written appeal, and external independent review — reverse a meaningful share of initial denials when the specific documentation gap that triggered the denial is identified and addressed. This article walks through why TMS denials happen, what each appeal level does, the California-specific Independent Medical Review pathway, and the division of labor between patient and clinic during the appeal.

Why TMS prior authorization gets denied

Almost every initial denial of TMS prior authorization falls into one of four categories. Recognizing which category applies is the first step of the appeal, because each category has a different remedy.

Inadequate documentation of antidepressant-trial failures. This is the single most common reason for denial. Most payer policies require documentation that the patient has failed at least two adequate antidepressant trials in the current episode, where "adequate" is defined as a therapeutic dose sustained for at least six weeks.¹ When the submitted record reflects medications tried but is missing dose, duration at dose, or the reason for discontinuation — a frequent gap when trials occurred under prior prescribers whose chart notes are not in hand — the reviewer cannot confirm the adequate-trial criterion and the request is denied on documentation grounds, not clinical grounds.

"Not medically necessary" determinations. In practice, "not medically necessary" rarely means the reviewer believes the patient is clinically inappropriate for TMS. It more often means the submitted clinical record does not make the case for treatment-resistant depression with enough specificity — a missing PHQ-9 baseline, a diagnosis recorded without the supporting DSM-5-TR criteria, or a treatment-history letter that summarizes the episode but does not cross-reference each criterion in the payer's policy. The Clinical TMS Society consensus framework is clear that the letter of medical necessity should establish the patient's treatment-resistance against the FDA-cleared indication language; a letter that does not do so reliably draws this denial.²

Coverage-policy mismatches. Some plans exclude TMS entirely; some apply criteria stricter than the carrier's standard medical policy (additional trial counts, additional psychotherapy requirements, lifetime medication-count thresholds); some apply criteria from an earlier version of the policy. A coverage-policy denial is a different problem from a documentation denial — the appeal must address the policy itself rather than supplying more clinical evidence.

Procedural and administrative denials. A small but persistent share of denials reflect process errors: the wrong CPT code for the requested protocol, a missing prescribing-clinician signature, a missing baseline rating scale, or a submission routed to the medical-benefit reviewer when the plan adjudicates TMS under the behavioral-health benefit. These are usually the fastest to reverse and are typically corrected with a resubmission rather than a formal appeal.

The three levels of appeal

The appeals path for TMS is structured as a graduated escalation. Each level provides a different forum and a different decision-maker, and the documentation gap that triggered the denial generally determines which level is most likely to reverse it.

Level 1 — Peer-to-peer review

A peer-to-peer review is a direct telephone conversation between the clinic's treating psychiatrist and the payer's medical director (or a designated reviewing physician). The request is generally placed within a small window after the denial — most plans schedule the call within 24 to 72 hours.

Peer-to-peer is, in practice, the fastest path to reversal because it lets the treating psychiatrist supply the clinical reasoning that did not fit into the written submission — for example, the rationale for declaring an antidepressant trial a failure earlier than six weeks because of an unmanageable side effect, or the clinical basis for treating a partial responder as treatment-resistant. The reviewing physician on the payer side has the authority to overturn the denial during the call. When the underlying issue is a documentation gap that can be closed by physician-to-physician clarification rather than by additional written records, peer-to-peer is the appropriate first step and frequently the only step required.

Level 2 — Formal written appeal

If peer-to-peer does not reverse the denial, the next step is a formal written appeal. The appeal is a fresh submission, reviewed by a physician other than the original reviewer, and the packet is substantially more developed than the original prior-authorization submission. A complete written appeal typically includes:

• A letter of medical necessity from the treating psychiatrist that cross-references each criterion in the payer's published medical policy point-by-point and explains, for each, how the clinical record meets it.²
• The full medication-trial history for the current episode, with dose, duration at therapeutic dose, response, side effects, and discontinuation reason for each agent — supplemented, where needed, with chart notes from outside prescribers.
• PHQ-9 (or equivalent) trajectories across the current episode, establishing baseline severity and the persistence of symptoms across trials.
• The chart note that establishes treatment-resistance under the relevant policy language.
• The relevant payer-policy criteria document itself, with the appeal letter responding to each criterion.
• For procedural denials, the corrected CPT coding, signatures, or baseline measures that the original submission was missing.

Commercial plans generally issue a written-appeal determination within 30 days; expedited reviews — where the standard timeframe would seriously jeopardize the patient's health — are required within 72 hours.³ Medicare Advantage and other plans subject to CMS-0057-F operate within the same 7-day standard and 72-hour expedited framework that governs the original prior-authorization decision.³ Original Medicare adjudicates coverage at the claim under the applicable Local Coverage Determination — there is no National Coverage Determination for TMS — and uses the standard Medicare claim-appeals process rather than a prior-authorization appeal.⁴

Level 3 — External independent review

When internal appeals are exhausted and the denial stands, the patient is entitled to an external independent review — a determination by a physician reviewer who is not employed by the payer and whose decision is binding on the payer. Every state offers an external-review pathway, and self-funded ERISA plans are subject to the federal external-review process under U.S. Department of Labor regulations.⁵ External review is the level at which a payer's adverse coverage policy can be tested against an independent clinical assessment, and it is the last administrative step before legal remedies.

The California-specific path

For patients receiving care in California, the external-review pathway runs through one of three tracks depending on the plan.

California Department of Managed Health Care (DMHC) — Independent Medical Review (IMR). Most HMO plans and many PPO plans in California are regulated by DMHC. The Independent Medical Review program, established under Cal. Health & Safety Code §1374.30 et seq., allows patients (or the clinic on the patient's behalf) to request review of a medical-necessity denial by an independent physician panel contracted by DMHC.⁶ IMR is free to the patient. Standard reviews are completed within approximately 30 days; expedited reviews — for cases in which the standard timeframe would seriously jeopardize the patient's health — are completed within 7 days. The IMR panel's decision is binding on the health plan. DMHC's annual IMR reporting indicates that mental-health-related medical-necessity denials, including TMS-related cases, have historically been reversed in favor of the patient in a substantial share of decisions — a meaningful base rate when weighing whether to pursue the appeal.⁶

California Department of Insurance (CDI). PPO plans underwritten by life or disability carriers — a subset of California PPO products — are regulated by CDI rather than DMHC. CDI operates a parallel IMR program under Cal. Insurance Code §10169 et seq., with the same independent-physician-panel structure and binding-on-the-insurer decision.⁷

Medicare Advantage. Medicare Advantage external appeals are handled outside the California IMR system, through the federal Independent Review Entity contractor — historically MAXIMUS Federal Services — which conducts the second-level review for adverse Medicare Advantage organization determinations.

Self-funded ERISA plans. Self-funded employer plans (the plan documents will identify the plan as self-funded) are governed by federal ERISA rather than California insurance law. External review for these plans follows the federal external-review process under 29 CFR §2560.503-1; the California IMR pathways do not apply.⁵

What the patient does, what the clinic does

The appeal — like the original prior authorization — is driven by the clinic, not the patient. The treating psychiatrist conducts the peer-to-peer review; the clinic's insurance team prepares the written appeal, assembles the supplemental documentation, requests records from outside prescribers, and submits the IMR or external-review application when escalation is warranted.

The patient's role during an appeal is narrower:

• Signing the appeals authorization form that permits the clinic to act on the patient's behalf with the carrier and, where applicable, with DMHC or the relevant external-review entity.
• Providing any missing source information the clinic needs to close the documentation gap — for example, identifying prior prescribers whose records are needed, or providing dates and dosing detail on prior trials.
• Continuing scheduled clinical visits during the appeal window so that the record under review remains current.

Patients should not contact the carrier directly during the appeal unless specifically instructed by the clinic. Carrier representatives reviewing the file may treat patient-initiated communication as parallel correspondence to the formal appeal, which can introduce inconsistencies into the record.

Timing, persistence, and the clinical clock

Appeals take time, and the time accumulates across levels. A peer-to-peer review is typically scheduled within 24 to 72 hours; a formal written appeal runs within 30 days for commercial plans (within 7 days for plans subject to CMS-0057-F);³ and an external review through DMHC is 30 days standard or 7 days expedited.⁶ In aggregate, a denial that escalates through all three levels may take 8 to 12 weeks to resolve.

The clinical clock matters, and it is the reason expedited review exists. When the patient's depressive episode is acute — and particularly when active suicidality is documented in the chart — the appeal should be filed as an expedited review with the clinical urgency stated explicitly in the request. Whether expedited review is granted is the payer's (or the external-review entity's) determination, but the request should be made when the clinical picture supports it.

Where the clinical picture cannot tolerate the appeals timeline, the clinic can advise on interim options — including initiating treatment under a self-pay arrangement during the appeal, with the understanding that retroactive reimbursement is not guaranteed even if the appeal is ultimately successful. This is a clinical and financial decision made jointly with the patient.

What the appeals process cannot do

Most denials reverse, but not all. Some plans genuinely exclude TMS from the benefit; some self-funded ERISA plans have plan-document language that the external reviewer is not empowered to override; some Medicare Advantage plans apply stricter criteria within the bounds of the relevant LCD that the appeal cannot meaningfully challenge. The honest framing is that the appeal is worth pursuing in the great majority of denial scenarios — and that, in the small subset where the appeal is unlikely to succeed, the clinic will say so plainly rather than run the patient through a multi-month process with no expected upside.

Key takeaways

• Most TMS prior-authorization denials are denials of documentation, not denials of clinical appropriateness — and the appeals path is structured to address that.
• The three appeal levels are peer-to-peer review (a same-day or next-day call between treating psychiatrist and payer medical director), formal written appeal (a developed written submission reviewed by a different physician within 30 days, or 7 days under CMS-0057-F), and external independent review (binding determination by a non-payer-employed physician).
• The four most common denial reasons are inadequate documentation of antidepressant trials, "not medically necessary" determinations driven by under-specific clinical records, coverage-policy mismatches, and procedural or administrative errors.
• California patients have access to the DMHC Independent Medical Review program (for HMO and most PPO plans), the parallel CDI IMR program (for life/disability-underwritten PPOs), the federal Medicare Advantage appeal track, and the federal ERISA external-review process for self-funded plans.
• The clinic drives the appeal; the patient's role is signing the appeals authorization, supplying missing source information, and continuing scheduled visits during the appeal window.
• Expedited review (72 hours for commercial, 7 days for DMHC IMR) is available where the standard timeframe would seriously jeopardize the patient's health, and should be requested explicitly when the clinical picture supports it.

For patients in Anaheim, Orange County, and the broader 30-mile radius who have received a denial of TMS prior authorization, the clinic's team conducts the peer-to-peer review, prepares the written appeal, and — where warranted — escalates to DMHC Independent Medical Review on the patient's behalf. The standard starting point is the insurance verification form, which routes a denied-coverage case directly to the appeals workflow. The TMS therapy page describes the clinical service the appeal is being sought for, and the companion article on the prior-authorization process for TMS covers the upstream submission flow that an appeal is reopening.

Sources / Further reading